The ROS1 gene is also a frequently mentioned gene mutation in lung cancer, but its mutation frequency is not particularly high.

In addition, many patients and their families do not clearly understand the mutation form of ROS1. Many unreliable gene sequencing companies have analyzed that a mutation at a site on the ROS1 gene is a drug-sensitive mutation, which has greatly interfered with the targeted medication of patients.

.

This article focuses on a systematic review of ROS1 gene mutation forms and corresponding targeted drugs.

Rearrangements of the ROS1 gene were first identified in human glioma cell lines. Subsequently, ROS1 gene rearrangements were also found in several other malignant tumors, such as cholangiocarcinoma, ovarian cancer, gastric cancer, and non-small cell carcinoma.

Lung cancer, of which the mutation frequency in non-small cell lung cancer is 1%-2%.

The ROS1 gene can undergo fusion mutations with multiple genes, the most important fusion partner of which is CD74 (see the picture below). When ROS1 is fused with other genes, the kinase domain is generally retained, and the breakpoint is relatively conserved.